INSM Overview

Company Profile

Related stocks

INCY • United States

Incyte Corporation

112.79 USD

22.86B USD 1Y +32.1%

HALO • United States

Halozyme Therapeutics, Inc.

110.42 USD

12.53B USD 1Y +68.5%

BBIO • United States

BridgeBio Pharma, Inc.

65.35 USD

12.78B USD 1Y +17.6%

EXEL • United States

Exelixis, Inc.

59.86 USD

14.83B USD 1Y +52.7%

AXSM • United States

Axsome Therapeutics, Inc.

168.35 USD

8.82B USD 1Y +43.3%

CAI • United States

Caris Life Sciences, Inc.

29.7 USD

8.39B USD 1Y -16.5%

RPRX • United States

Royalty Pharma plc

56.93 USD

32.9B USD 1Y +56.1%

CORT • United States

Corcept Therapeutics Incorporat

121.19 USD

13.1B USD 1Y +34%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile

4 Metrics

Country

Region

Sector

Industry

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High

5Y Volatility

74.2% p.a.

Max Drawdown (5Y)

-56.5%

Sharpe Ratio (5Y)

0.35

Beta Factor

0.82

Size Class

Large Cap

Notes & Warnings

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).

🔴 High valuation risk: Avg P/E of 127.8 (Elevated multiple compression risk)

Elevated Short-Term Volatility: 3Y volatility (85.7%) is noticeably higher than the 5Y average (74.2%).

Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (74.2% p.a.).

Historical Stress Test: Maximum peak-to-trough drawdown of -64.8% in the extended horizon.